Burning through the pain: treatments for diabetic neuropathy

@article{Javed2015BurningTT,
  title={Burning through the pain: treatments for diabetic neuropathy},
  author={Saad Javed and Uazman Alam and Rayaz Ahmed Malik},
  journal={Diabetes},
  year={2015},
  volume={17}
}
The rise in the global burden of diabetes is spurring an increase in the prevalence of its complications. Diabetic peripheral neuropathy (DPN) is a common and devastating complication of diabetes, with multiple clinical manifestations. The most common is a symmetrical length‐dependent dysfunction and damage of peripheral nerves. The management of DPN rests on three tenets: intensive glycaemic control, even though the evidence of benefit is questionable in people with type 2 diabetes… Expand
Emerging drugs for diabetic peripheral neuropathy and neuropathic pain
TLDR
An array of promising molecular entities have reached the clinical stage of development, which should improve the therapeutic armamentarium in the fight against DSPN and neuropathic pain in the foreseeable future. Expand
The Role of Nuclear Factor Erythroid 2-Related Factors (Nrf2) in Diabetic Neuropathy: A Literature Review
TLDR
The last few decades of research suggest that there are transcription factors that affect the incidence of diabetic neuropathy, and these factors will be discussed in this article. Expand
How to prevent the microvascular complications of type 2 diabetes beyond glucose control
TLDR
Interventions discussed include standard of care interventions supported by guidelines from major organizations, as well as additional proposed interventions that are supported by research published in the past decade. Expand
Relationship Between Glycated Hemoglobin and Vibration Perception Threshold in Diabetic Peripheral Neuropathy
TLDR
There is strong relationship between HbA1c values and VPT and could be a predictor for complications in the foot following DPN, the present study has concluded. Expand
Botulinum Toxin Treatment of Neuropathic Pain.
TLDR
The data indicate that BoNT treatment (most of the literature is with onabotulinumtoxinA) is effective (level A evidence) in postherpetic neuralgia and trigeminal Neuralgia, and it is probably effective in posttraumatic neuralGia and painful diabetic neuropathy. Expand
Aerobic exercise training may improve nerve function in type 2 diabetes and pre‐diabetes: A systematic review
TLDR
Evidence from this systematic review suggests aerobic exercise training may positively influence nerve function among people with type 2 diabetes, with minimal risk of adverse events. Expand
microRNA-155 silencing reduces sciatic nerve injury in diabetic peripheral neuropathy.
TLDR
Evidence is provided indicating that miR-155 targeted and suppressed Nrf2 in DPN, highlighting its potential as a therapeutic target for DPN. Expand
Tapentadol Prolonged Release Reduces the Severe Chronic Ischaemic Pain and Improves the Quality of Life in Patients with Type 2 Diabetes
TLDR
In type 2 diabetic patients with chronic severe pain due to PAD, tapentadol PR reduced pain intensity, improving the quality of life. Expand
TARGETING METHYLGLYOXAL AND PPAR GAMMA TO ALLEVIATE NEUROPATHIC PAIN ASSOCIATED WITH TYPE 2 DIABETES
TLDR
This work is the first to show a measure of motivational-affective pain in a model of type 2 diabetes and tested the hypothesis that methylglyoxal produces nociceptive, evoked, and affective pain that is dependent on activation of the sensory neuron cation channel TRPA1 and the secondary messenger enzyme AC1. Expand
The Dos and Don'ts of Painful Diabetic Peripheral Neuropathy : Primary Care Guidelines for the Middle East and North Africa
TLDR
PDPN is common but under-diagnosed and inadequately treated in the Middle East and North Africa and Physicians in the region are encouraged to implement screening for pDPN and manage patients according to published guidelines. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 106 REFERENCES
Diabetic painful neuropathy: current and future treatment options.
TLDR
Evidence from placebo-controlled studies has shown that opioids, antiepileptic and antidepressant drugs together with capsaicin are effective for alleviating DPN, and the potential availability of less expensive generic formulations of gabapentin and pregabalin appear to be the most evidence-based of the antiePileptic drugs for treating DPN. Expand
Why are there no good treatments for diabetic neuropathy?
  • R. Malik
  • Medicine
  • The lancet. Diabetes & endocrinology
  • 2014
TLDR
Non-invasive, sensitive, and reproducible measures of nerve damage and repair are urgently needed to use as surrogate markers in clinical trials of diabetic neuropathy. Expand
Diabetic neuropathy: clinical manifestations and current treatments
TLDR
Growing evidence supports an association between components of the metabolic syndrome, including prediabetes, and neuropathy, and studies are needed to further explore this association, which has implications for the development of new treatments for this common disorder. Expand
Diabetic neuropathy: cellular mechanisms as therapeutic targets
TLDR
The emerging cellular mechanisms that are activated in the diabetic milieu of hyperglycemia, dyslipidemia and impaired insulin signaling are discussed, thereby identifying promising therapeutic targets, including mitochondrial function and inflammation. Expand
Painful diabetic peripheral neuropathy: consensus recommendations on diagnosis, assessment and management
TLDR
There are a number of unmet needs in the therapeutic management of painful DPN, including the need for randomized controlled trials with active comparators and data on the long‐term efficacy of agents used, as most trials have lasted for less than 6 months. Expand
Ruboxistaurin for the Treatment of Diabetic Peripheral Neuropathy: A Systematic Review of Randomized Clinical Trials
TLDR
RBX had effects on DPN in some studies, but the evidence is not enough for meta-analysis and firm conclusion. Expand
Aldose reductase inhibitors for the treatment of diabetic polyneuropathy.
TLDR
No statistically significant difference was found between aldose reductase inhibitors and placebo in the treatment of diabetic polyneuropathy, and three compounds had dose limiting adverse events that lead to their withdrawal from human use. Expand
Mechanisms and Management of Diabetic Painful Distal Symmetrical Polyneuropathy
TLDR
A number of pharmacological agents have proven efficacy in painful DSPN, but all are prone to side effects, and none impact the underlying pathophysiological abnormalities because they are only symptomatic therapy. Expand
Whither pathogenetic treatments for diabetic polyneuropathy?
TLDR
Some pathogenetic therapies have shown clinically relevant improvements in neuropathic endpoints in randomised controlled trials, in particular α‐lipoic acid and Actovegin. Expand
New insights into the metabolic and molecular basis for diabetic neuropathy
  • A. Sima
  • Medicine
  • Cellular and Molecular Life Sciences CMLS
  • 2003
TLDR
There is now evidence to suggest that insulin and C-peptide deficiencies are mainly responsible for perturbations of neurotrophic factors and contribute to oxidative stress in diabetic nerve, which may also be true for apoptotic phenomena afflicting both the peripheral and central nervous systems in diabetes. Expand
...
1
2
3
4
5
...